WO2021159040A3 - Sars-cov-2 mrna domain vaccines - Google Patents

Sars-cov-2 mrna domain vaccines Download PDF

Info

Publication number
WO2021159040A3
WO2021159040A3 PCT/US2021/016979 US2021016979W WO2021159040A3 WO 2021159040 A3 WO2021159040 A3 WO 2021159040A3 US 2021016979 W US2021016979 W US 2021016979W WO 2021159040 A3 WO2021159040 A3 WO 2021159040A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
cov
sars
mrna domain
mrna
Prior art date
Application number
PCT/US2021/016979
Other languages
French (fr)
Other versions
WO2021159040A2 (en
WO2021159040A9 (en
Inventor
Guillaume Stewart-Jones
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP21709270.9A priority Critical patent/EP4100052A2/en
Priority to MX2022009707A priority patent/MX2022009707A/en
Priority to JP2022548194A priority patent/JP7438604B2/en
Priority to KR1020227028371A priority patent/KR20220140528A/en
Priority to BR112022015565A priority patent/BR112022015565A2/en
Priority to IL295377A priority patent/IL295377A/en
Priority to CN202180013506.4A priority patent/CN115551545A/en
Priority to CA3170150A priority patent/CA3170150A1/en
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Priority to US17/797,784 priority patent/US20230346914A1/en
Priority to AU2021215938A priority patent/AU2021215938A1/en
Publication of WO2021159040A2 publication Critical patent/WO2021159040A2/en
Publication of WO2021159040A3 publication Critical patent/WO2021159040A3/en
Publication of WO2021159040A9 publication Critical patent/WO2021159040A9/en
Priority to JP2023132619A priority patent/JP7443608B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Abstract

The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.
PCT/US2021/016979 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines WO2021159040A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN202180013506.4A CN115551545A (en) 2020-02-07 2021-02-06 SARS-COV-2 mRNA structure domain vaccine
JP2022548194A JP7438604B2 (en) 2020-02-07 2021-02-06 SARS-COV-2 mRNA domain vaccine
KR1020227028371A KR20220140528A (en) 2020-02-07 2021-02-06 SARS-COV-2 mRNA domain vaccine
BR112022015565A BR112022015565A2 (en) 2020-02-07 2021-02-06 MRNA DOMAIN VACCINES FOR SARS-COV-2
IL295377A IL295377A (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines
EP21709270.9A EP4100052A2 (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines
CA3170150A CA3170150A1 (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines
MX2022009707A MX2022009707A (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines.
US17/797,784 US20230346914A1 (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines
AU2021215938A AU2021215938A1 (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines
JP2023132619A JP7443608B2 (en) 2020-02-07 2023-08-16 SARS-COV-2 mRNA domain vaccine

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062971825P 2020-02-07 2020-02-07
US62/971,825 2020-02-07
US202063016175P 2020-04-27 2020-04-27
US63/016,175 2020-04-27
US202063044330P 2020-06-25 2020-06-25
US63/044,330 2020-06-25
US202063063137P 2020-08-07 2020-08-07
US63/063,137 2020-08-07

Publications (3)

Publication Number Publication Date
WO2021159040A2 WO2021159040A2 (en) 2021-08-12
WO2021159040A3 true WO2021159040A3 (en) 2021-11-04
WO2021159040A9 WO2021159040A9 (en) 2021-11-25

Family

ID=74845093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/016979 WO2021159040A2 (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines

Country Status (11)

Country Link
US (1) US20230346914A1 (en)
EP (1) EP4100052A2 (en)
JP (2) JP7438604B2 (en)
KR (1) KR20220140528A (en)
CN (1) CN115551545A (en)
AU (1) AU2021215938A1 (en)
BR (1) BR112022015565A2 (en)
CA (1) CA3170150A1 (en)
IL (1) IL295377A (en)
MX (1) MX2022009707A (en)
WO (1) WO2021159040A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
JP6921833B2 (en) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド Human cytomegalovirus vaccine
HRP20220872T1 (en) 2015-10-22 2022-12-23 Modernatx, Inc. Respiratory virus vaccines
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
MA46584A (en) 2016-10-21 2019-08-28 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (en) 2016-11-11 2019-09-18 Modernatx Inc INFLUENZA VACCINE
MA47787A (en) 2017-03-15 2020-01-22 Modernatx Inc RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
MA52262A (en) 2017-03-15 2020-02-19 Modernatx Inc BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
MA49922A (en) 2017-08-18 2021-06-02 Modernatx Inc PROCESSES FOR HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. Analytical hplc methods
JP7408098B2 (en) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド RNA polymerase variants
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
GB202307565D0 (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
KR20230011369A (en) * 2020-05-18 2023-01-20 칸시노 (상하이) 바이오테크놀로지스 컴퍼니 리미티드 mRNA or mRNA composition and methods for its preparation and uses thereof
EP4199963A1 (en) * 2020-08-24 2023-06-28 Phylex Biosciences, Inc. Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
AU2022208057A1 (en) * 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
US11524023B2 (en) * 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
JP2024511346A (en) * 2021-03-15 2024-03-13 モデルナティエックス インコーポレイテッド Therapeutic use of SARS-COV-2 mRNA domain vaccines
WO2022235853A1 (en) 2021-05-04 2022-11-10 BioNTech SE Immunogen selection
WO2023022954A1 (en) * 2021-08-15 2023-02-23 Burton Dennis R Undirected mutated mrna vaccine
AU2022330710A1 (en) * 2021-08-17 2024-01-18 Monash University Vaccine compositions
AU2022333308A1 (en) * 2021-08-24 2024-03-07 Victoria Link Limited Fusion polypeptide
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
CN113527522B (en) * 2021-09-13 2021-12-21 深圳市瑞吉生物科技有限公司 New coronavirus trimer recombinant protein, DNA, mRNA, application and mRNA vaccine
CN116064598B (en) * 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus
WO2023060483A1 (en) * 2021-10-13 2023-04-20 清华大学 Polypeptide-rbd immunoconjugate and use thereof
WO2023066496A1 (en) 2021-10-21 2023-04-27 BioNTech SE Coronavirus vaccine
WO2023064993A1 (en) * 2021-10-21 2023-04-27 The University Of Melbourne Chimeric betacoronavirus spike polypeptides
WO2023092069A1 (en) * 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
WO2023096990A1 (en) * 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
TW202333780A (en) 2021-11-29 2023-09-01 德商拜恩技術股份公司 Coronavirus vaccine
IL288634A (en) * 2021-12-02 2023-07-01 Yeda Res & Dev Improving the translation and protein secretion efficiency of mrna vaccines
WO2023113094A1 (en) * 2021-12-16 2023-06-22 주식회사 씨티씨백 Covid-19 vaccine composition with increased immunogenicity
WO2023125974A1 (en) * 2021-12-31 2023-07-06 广州国家实验室 Mrna vaccine
WO2023142283A1 (en) 2022-01-27 2023-08-03 深圳市瑞吉生物科技有限公司 Sars-cov-2 mrna vaccine, and preparation method therefor and use thereof
AU2022369834A1 (en) * 2022-01-27 2023-08-10 Shenzhen Rhegen Biotechnology Co., Ltd. SARS-CoV-2 mRNA Vaccine and Preparation Method and Use Thereof
CN116514671A (en) * 2022-01-30 2023-08-01 康希诺生物股份公司 Novel ionizable lipids for nucleic acid delivery and LNP compositions and vaccines thereof
CN114213509B (en) * 2022-02-22 2022-06-10 广州市锐博生物科技有限公司 S protein vaccine based on SARS-CoV-2 and its use
CN116726162A (en) * 2022-03-11 2023-09-12 病毒与疫苗研究中心有限公司 Vaccine boosting composition for respiratory viral diseases
KR20230144421A (en) * 2022-04-07 2023-10-16 엠큐렉스 주식회사 RNA vaccines against SARS-Coronavirus 2 infection
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
US20190351048A1 (en) * 2016-12-23 2019-11-21 Curevac Ag Mers coronavirus vaccine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (en) 2001-04-30 2002-11-07 Christos C Zouboulis Acne treatment
EP1800697B1 (en) 2001-06-05 2010-04-14 CureVac GmbH Stabilised mRNA with increased G/C-content for use in gene therapy
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
CN101977510A (en) 2007-06-29 2011-02-16 联邦科学技术研究组织 Methods for degrading toxic compounds
EP2535419A3 (en) 2007-09-26 2013-05-29 Intrexon Corporation Synthetic 5'UTRs, expression vectors, and methods for increasing transgene expression
WO2009075886A1 (en) 2007-12-11 2009-06-18 The Scripps Research Institute Compositions and methods related to mrna translational enhancer elements
BR112012002291A2 (en) 2009-07-31 2016-11-29 Ethris Gmbh "polyribonucleotide with a sequence encoding a protein or protein fragment, implant, and process for selecting nucleotide sequences"
PL2717893T3 (en) 2011-06-08 2019-12-31 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
MX2014015041A (en) 2012-06-08 2015-06-17 Shire Human Genetic Therapies Pulmonary delivery of mrna to non-lung target cells.
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
AU2014239184B2 (en) 2013-03-14 2018-11-08 Translate Bio, Inc. Methods and compositions for delivering mRNA coded antibodies
US10130649B2 (en) 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
ES2702466T3 (en) 2013-08-21 2019-03-01 Curevac Ag Procedure to increase the expression of proteins encoded by RNA
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
RU2717986C2 (en) 2013-12-30 2020-03-27 Куревак Аг Artificial molecules of nucleic acid
JP6584414B2 (en) 2013-12-30 2019-10-02 キュアバック アーゲー Artificial nucleic acid molecule
HRP20220070T1 (en) 2014-04-23 2022-04-01 Modernatx, Inc. Nucleic acid vaccines
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. High potency immunogenic compositions
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
JP7408098B2 (en) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド RNA polymerase variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
US20190351048A1 (en) * 2016-12-23 2019-11-21 Curevac Ag Mers coronavirus vaccine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 15 January 2020 (2020-01-15), ZHANG Y.-Z. ET AL: "Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome.", XP055796635, Database accession no. MN908947 *
HUANG CHAOLIN ET AL: "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 395, no. 10223, 24 January 2020 (2020-01-24), pages 497 - 506, XP086050317, ISSN: 0140-6736, [retrieved on 20200124], DOI: 10.1016/S0140-6736(20)30183-5 *
JIAMING LAN ET AL: "The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection", VACCINE, vol. 35, no. 1, 2017, pages 10 - 18, XP029841627, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2016.11.064 *
LI FANG: "Structure, Function, and Evolution of Coronavirus Spike Proteins", ANNUAL REVIEW OF VIROLOGY, vol. 3, no. 1, 29 September 2016 (2016-09-29), USA, pages 237 - 261, XP055807566, ISSN: 2327-056X, Retrieved from the Internet <URL:https://www.annualreviews.org/doi/pdf/10.1146/annurev-virology-110615-042301> DOI: 10.1146/annurev-virology-110615-042301 *
MA CUIQING ET AL: "Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines", VACCINE, vol. 32, no. 18, 2014, pages 2100 - 2108, XP028838491, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2014.02.004 *
YIN LIJUAN ET AL: "Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens", VIRUS RESEARCH, AMSTERDAM, NL, vol. 223, 3 August 2016 (2016-08-03), pages 206 - 212, XP029698726, ISSN: 0168-1702, DOI: 10.1016/J.VIRUSRES.2016.07.010 *

Also Published As

Publication number Publication date
MX2022009707A (en) 2022-09-07
KR20220140528A (en) 2022-10-18
BR112022015565A2 (en) 2022-09-27
JP7438604B2 (en) 2024-02-27
CN115551545A (en) 2022-12-30
EP4100052A2 (en) 2022-12-14
JP7443608B2 (en) 2024-03-05
JP2023513544A (en) 2023-03-31
IL295377A (en) 2022-10-01
US20230346914A1 (en) 2023-11-02
JP2023153256A (en) 2023-10-17
CA3170150A1 (en) 2021-08-12
WO2021159040A2 (en) 2021-08-12
WO2021159040A9 (en) 2021-11-25
AU2021215938A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
WO2021159040A3 (en) Sars-cov-2 mrna domain vaccines
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
MX2022009280A (en) Coronavirus rna vaccines.
WO2021155243A8 (en) Respiratory virus immunizing compositions
WO2023283642A3 (en) Pan-human coronavirus concatemeric vaccines
WO2022221359A8 (en) Epstein-barr virus mrna vaccines
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2011063308A8 (en) Beta-glucosidase i variants with improved properties
WO2007089335A3 (en) Multicyclic amino acid derivatives and methods of their use
NO20064976L (en) Azanidols useful as inhibitors of rock and other protein kinases
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
MXPA06011327A (en) Azaindoles useful as inhibitors of jak and other protein kinases.
WO2010115206A3 (en) Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
EA200970177A1 (en) COMPOSITION AND METHOD OF OBTAINING PROPPANTS
WO2005028628A3 (en) Modulation of eif4e expression
NO20071078L (en) Antiviral compounds
NO20070866L (en) Antiviral compounds.
WO2009135212A3 (en) Selective 5&#39; ligation tagging of rna
BR112012032193A2 (en) phenylthioacetate compound, compositions and methods of use
EA200800838A1 (en) MODULATION OF IMMUNE MULTIRATION PROPERTIES OF SHORT INTERFERRING RIBONUCLEIC ACID (SIPHK) BY MEANS OF NUCLEOTIDE MODIFICATION
WO2011048553A3 (en) Pharmaceutical compositions of pde-5 inhibitors and dapoxetine
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
MX2022002946A (en) Cdk inhibitors and their use as pharmaceuticals.
WO2005049832A3 (en) FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2022039822A8 (en) Methods and compositions for treating coronavirus infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21709270

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3170150

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022548194

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022015565

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021215938

Country of ref document: AU

Date of ref document: 20210206

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021709270

Country of ref document: EP

Effective date: 20220907

ENP Entry into the national phase

Ref document number: 112022015565

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220805